Who founded Amalgent?

Amalgent was founded by Sam Tetlow, Malcolm Meyn in 2020.

Who are Amalgent's investors?

Amalgent's investors include The Innovation Space.

How much funding has Amalgent raised?

Amalgent has disclosed $200K raised across 1 round.

Where is Amalgent headquartered?

Amalgent is headquartered in Chapel Hill, US.

Amalgent

Chapel Hill, US · Founded 2020 · Delaware LLC · 2 employees on LinkedIn · 1 known investors

Find your way into Amalgent

Paths you didn't know you had: your email and LinkedIn already hold routes to the Amalgent team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Amalgent is a clinical-stage pain management company developing oral combination drug therapeutics that repurpose existing medications to improve the safety of severe pain treatment. It initially targets the US market.

Biotech Healthtech

Founders & leadership

Amalgent was founded in 2020 by Sam Tetlow and Malcolm Meyn.

Sam Tetlow Co-Founder and Chief Scientific OfficerSam Tetlow is a biotechnology executive with over 20 years of experience in drug development strategy, R&D organization, and advancing small-molecule and biologic programs. He previously held research positions as a Howard Hughes Medical Institute Fellow at Penn and Research Professor at University of Pittsburgh studying stem cell biology, directed preclinical programs at Noveome Biotherapeutics, and operates a consulting practice advising biopharma clients on development strategy and regulatory pathways.

Malcolm Meyn Co-founder & Chief Scientific OfficerMalcolm Meyn is a co-founder and Chief Scientific Officer of Amalgent Therapeutics, a clinical-stage pain management company. He brings over 20 years of biotechnology experience in small-molecule and biologic drug development, including prior roles as a Howard Hughes Medical Institute Fellow at the University of Pennsylvania and Research Professor at the University of Pittsburgh studying stem cell biology, as well as preclinical leadership at Noveome Biotherapeutics.

GeraldChief Medical Officer

AndrewChief Finance Officer

Investors · 1

The Innovation Spacelisted by The Innovation SpaceWilmington · $200K

How we know: The Innovation Space's portfolio page · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$200K disclosed across 1 round · 2022

▶$200KraisedApr 2022 · 1 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Malcolm A MeynExecutive Officer, Director
Sam TetlowDirector

Offering amount: $1M
Amount sold: $200K
First sale: Apr 2022
Incorporated: Limited Liability Company, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 4

Emergent BiosolutionsEmergent BioSolutions is a public health company that develops, manufactures, and supplies medical countermeasures for national security and preparedness, along with commercialized products addressing threats such as the opioid epidemic. It also provides in-house development and manufacturing support to biopharma innovators, governments, and non-governmental organizations.

SchrodingerSchrödinger develops a physics-based computational platform for discovering and optimizing molecules, used to accelerate drug discovery and materials design. The company also operates a therapeutics group that pursues drug development on validated targets and offers educational resources for the field.

GentiBioGentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases. The company builds autologous and allogeneic Treg platforms as an alternative to systemic immune-suppressive therapies.

TevaTeva Pharmaceuticals is a global pharmaceutical company that discovers, develops, and manufactures medicines to treat chronic conditions for patients across 57 markets. The company operates through approximately 37,000 employees focused on improving health outcomes and delivering quality treatments worldwide.

Companies working in the same space as Amalgent.

Frequently asked questions

What does Amalgent do?: Amalgent is a clinical-stage pain management company developing oral combination drug therapeutics that repurpose existing medications to improve the safety of severe pain treatment. It initially targets the US market.
Who founded Amalgent?: Amalgent was founded by Sam Tetlow, Malcolm Meyn in 2020.
Who are Amalgent's investors?: Amalgent's investors include The Innovation Space.
How much funding has Amalgent raised?: Amalgent has disclosed $200K raised across 1 round.
Where is Amalgent headquartered?: Amalgent is headquartered in Chapel Hill, US.